Company intelligence / Profile preview

Journey Biosciences

Cleveland, Ohio, United States

Ownership: Private
Employees: ~19
Development stage: Other

Overview

Journey Biosciences commercially offers NaviDKD, an FDA-approved and clinically validated blood-based predictive screening that uses advanced glycation end-product biomarkers and clinical data, combined with its Compass AI platform, to stratify adults with diabetes into risk categories for developing diabetes-related kidney disease up to ~12 years before typical clinical detection.[3][4][5][1]

Therapeutic areas: Nephrology
Modalities: DiagnosticDeviceNon-pharmacological therapy
Industry: Protein Biomarker Diagnostics

Partnerships

Cardinal Health OptiFreight Logistics

Beyond the preview

Go deeper on Journey Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Journey Biosciences.

Explore the full profile